| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia DA Arber, A Orazi, R Hasserjian, J Thiele, MJ Borowitz, MM Le Beau, ... Blood 127 (20), 2391-2405, 2016 | 5437 | 2016 |
| A gain-of-function mutation of JAK2 in myeloproliferative disorders R Kralovics, F Passamonti, AS Buser, SS Teo, R Tiedt, JR Passweg, ... New England Journal of Medicine 352 (17), 1779-1790, 2005 | 3905 | 2005 |
| Revised international prognostic scoring system for myelodysplastic syndromes PL Greenberg, H Tuechler, J Schanz, G Sanz, G Garcia-Manero, F Solé, ... Blood 120 (12), 2454-2465, 2012 | 2139 | 2012 |
| Somatic mutations of calreticulin in myeloproliferative neoplasms KR Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi New England Journal of Medicine 369 (25), 2379-2390, 2013 | 1750 | 2013 |
| Clinical and biological implications of driver mutations in myelodysplastic syndromes E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ... Blood 122 (22), 3616-3627, 2013 | 1318 | 2013 |
| Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. L Malcovati, U Germing, A Kuendgen, MG Della Porta, C Pascutto, ... Journal of clinical oncology 25 (23), 3503-3510, 2007 | 1133 | 2007 |
| Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ... New England Journal of Medicine 365 (15), 1384-1395, 2011 | 1101 | 2011 |
| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1061 | 2013 |
| Efficacy and safety of low-dose aspirin in polycythemia vera R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ... New England Journal of Medicine 350 (2), 114-124, 2004 | 1039 | 2004 |
| Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ... Journal of Clinical Oncology 23 (30), 7594-7603, 2005 | 998 | 2005 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood 115 (9), 1703-1708, 2010 | 761 | 2010 |
| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... N Engl J Med 368, 22-33, 2013 | 656 | 2013 |
| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 601 | 2013 |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet L Malcovati, E Hellström-Lindberg, D Bowen, L Ades, J Cermak, ... Blood 122 (17), 2943-2964, 2013 | 566 | 2013 |
| JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ... Blood 123 (10), 1544-1551, 2014 | 554 | 2014 |
| Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ... The American journal of medicine 117 (10), 755-761, 2004 | 525 | 2004 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 523 | 2013 |
| Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms L Malcovati, E Papaemmanuil, DT Bowen, J Boultwood, MG Della Porta, ... Blood, The Journal of the American Society of Hematology 118 (24), 6239-6246, 2011 | 456 | 2011 |
| A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q P Fenaux, A Giagounidis, D Selleslag, O Beyne-Rauzy, G Mufti, ... Blood 118 (14), 3765-3776, 2011 | 427 | 2011 |
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ... Blood 123 (21), 3247-3254, 2014 | 426 | 2014 |
Malcovati LucaUniversity of PaviaVerified email at unipv.it
